AD therapy is commonly based on inhibitors of acetylcholinesterase (AChE), the enzyme responsible to the hydrolysis of acetylcholine in several cholinergic pathways in the central and peripheral nervous systems. The gene discussed is ACHE; the disease is Alzheimer disease.